Objective To analyze the factors influencing breast cancer patients with 1-2 positive sentinel lymph nodes which meets ACOSGO Z0011 criteria without further axillary lymph node dissection (ALND) and their prognosis. Methods Patients with cT1-2N0 invasive breast cancer received breast conserving surgery and radiotherapy were enrolled retrospectively in Comprehensive Breast Health Center, Rujin Hospital between January 2012 and August 2019. Factors which influenced not to receive further ALND in patients with 1-2 positive sentinel lymph node and its association with prognosis were analyzed. Results were listed as odds ratio and 95% confidence interval. Results A total of 161 patients were studied, including 78 patients without ALND in the SLNB group and 83 patients in the ALND group. There were 11 (13.3%) patients with non-SLN metastasis and 4 (4.8%) patients with 3 axillary lymph node (ALN) metastasis in the ALND group. Both univariate and multivariate analysis found that surgical-year was associated with ALND (P<0.001). Patients in more recent surgical-year were received less ALND. Eleven (14.1%) and 6 (3.6%) patients in the SLNB and ALND groups had no further adjuvant chemotherapy, respectively. Univariate analysis showed that age (P<0.001), menopausal status (P=0.016), and ALN surgery(P=0.018) were related with adjuvant chemotherapy. Multivariate analysis showed that only age was independently related with chemotherapy(P<0.001). With a median follow up of 42.0 months, ALN recurrence was found only 1 (1.3%) patient in the SLNB group and none in the ALND group. Conclusions Patients with 1-2 positive sentinel nodes who met the eligible criteria of ACOSOG Z0011 trial could be treated without ALND. The association of ALND with long-term survival deserves further evaluation.
CHEN Xiaosong, WU Jiayi, HUANG Ou, HE Jianrong, ZHU Li, LI Yafen, CHEN Weiguo, SHEN Kunwei
. Breast cancer patients with 1-2 positive sentinel lymph nodes without axillary lymph node dissection: influencing factors and prognosis[J]. Journal of Surgery Concepts & Practice, 2019
, 24(05)
: 428
-433
.
DOI: 10.16139/j.1007-9610.2019.05.012
[1] Lyman GH, Somerfield MR, Bosserman LD, et al.Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update[J]. J Clin Oncol,2017, 35(5):561-564.
[2] Giuliano AE, Hunt KK, Ballman KV, et al.Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A rando-mized clinical trial[J]. JAMA,2011,305(6):569-575.
[3] Harbeck N, Gnant M.Breast cancer[J]. Lancet,2017,389(10074):1134-1150.
[4] Krag DN, Anderson SJ, Julian TB, et al.Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol,2010,11(10):927-933.
[5] Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial[J]. JAMA,2017,318(10):918-926.
[6] Galimberti V, Cole BF, Viale G, et al.Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial[J]. Lancet Oncol,2018,19(10):1385-1393.
[7] Yi M, Kuerer HM, Mittendorf EA, et al.Impact of the American College of Surgeons Oncology Group Z0011 criteria applied to a contemporary patient population[J]. J Am Coll Surg,2013,216(1):105-113.
[8] Chung A, Gangi A, Mirocha J, et al.Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery[J]. Ann Surg Oncol,2015,22(4):1128-1132.
[9] Dengel LT, van Zee KJ, King TA, et al. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy[J]. Ann Surg Oncol,2014,21(1):22-27.
[10] Delpech Y, Bricou A, Lousquy R, et al.The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study[J]. Ann Surg Oncol,2013,20(8):2556-2561.
[11] Howard DH, Soulos PR, Chagpar AB, et al.Contrary to conventional wisdom, physicians abandoned a breast cancer treatment after a trial concluded it was ineffective[J]. Health Aff (Millwood),2016,35(7):1309-1315.
[12] Poodt IGM, Spronk PER, Vugts G, et al.Trends on axillary surgery in nondistant metastatic breast cancer patients treated between 2011 and 2015: a Dutch population-based study in the ACOSOG-Z0011 and AMAROS era[J]. Ann Surg,2018,268(6):1084-1090.
[13] Liang Y, Chen X, Zhan W, et al.Can clinically node-negative breast cancer patients with suspicious axillary lymph nodes at ultrasound but negative fine-needle aspiration be approached as having node-negative disease?[J] Ann Surg Oncol,2017,24(7):1874-1880.
[14] Curigliano G, Burstein HJ, Winer EP, et al.De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017[J]. Ann Oncol,2017,28(8):1700-1712.
